Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

Breast Cancer Research

Table 2 Estimation of the benefit from adjuvant tamoxifen treatment

Tumor status	Tamoxifen treatment versus no endocrine treatment
	Distant recurrence			Breast cancer death
	Hazard ratio (95% CI)	P value	P _interaction*	Hazard ratio (95% CI)	P value	P _interaction*
ER-positive
Low HOXB13 expression	0.38 (0.23 to 0.60)	0.000048		0.35 (0.20 to 0.60)	0.00016
High HOXB13 expression	0.88 (0.47 to 1.65)	0.69	0.035	0.84 (0.37 to 1.90)	0.67	0.060
ER-positive, PR-positive
Low HOXB13 expression	0.26 (0.14 to 0.49)	0.000022		0.24 (0.11 to 0.50)	0.00015
High HOXB13 expression	0.70 (0.31 to 1.56)	0.38	0.072	0.82 (0.27 to 2.56)	0.74	0.059
ER-positive, PR-negative
Low HOXB13 expression	0.69 (0.31 to 1.56)	0.37		0.64 (0.26 to 1.56)	0.33
High HOXB13 expression	0.89 (0.31 to 2.54)	0.83	0.51	0.60 (0.17 to 2.13)	0.43	0.98

Cox regression analysis of distant recurrence rate and breast cancer-related deaths for patients with estrogen receptor (ER)-positive tumors, ER-positive and progesterone receptor (PR)-positive tumors, and ER-positive and PR-negative tumors in relation to HOXB13 protein expression. CI, confidence interval. *Tests whether there is a difference in the treatment response. The models included treatment (tamoxifen vs. no endocrine treatment), HOXB13 expression (high vs. low), an interaction variable, tumor size (>20 mm vs. ≤20 mm) and HER2 status (3+ vs. 0 to 2+).

ISSN: 1465-542X